Search
Acylcarnitine 20-Methyldocosanoylcarnitine
smpdb.ca/view/SMP0123753Metabolic20-Methyldocosanoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, 20-methyldocosanoyl-CoA reacts with L-carnitine to form 20-methyldocosanoylcarnitine. This reaction is catalyzed by carnitine O-palmitoyltransferase.
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreAcylcarnitine 20-Methyltricosanoylcarnitine
smpdb.ca/view/SMP0123764Metabolic20-Methyltricosanoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, 20-methyltricosanoyl-CoA reacts with L-carnitine to form 20-methyltricosanoylcarnitine. This reaction is catalyzed by carnitine O-palmitoyltransferase.
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreAcylcarnitine 20-Methylpentacosanoylcarnitine
smpdb.ca/view/SMP0123804Metabolic20-Methylpentacosanoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, 20-methylpentacosanoyl-CoA reacts with L-carnitine to form 20-methylpentacosanoylcarnitine. This reaction is catalyzed by carnitine O-palmitoyltransferase.
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreDanicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction … [A263506] It was subsequently approved by the FDA in March 2024.[L50386]
Categories: Complement Factor D InhibitorSynonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideFosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalIn April 2018, the U.S. … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.
Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
smpdb.ca/view/SMP0248907MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
smpdb.ca/view/SMP0249104MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(20:3(11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))
smpdb.ca/view/SMP0250444MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))
smpdb.ca/view/SMP0250642MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.